Department of Pharmaceuticals accepted the representation for amendment of the GTE relaxation list, now under active stakeholder consultation (DoP Public Notice dated 11 February 2026), enabling faster procurement pathways for advanced diagnostics at public hospitals.
Unlocks direct procurement of advanced diagnostic systems without case-by-case Cabinet Secretariat escalation. For technologies like digital PET-CT with fewer than three global manufacturers, procurement delay translates directly into delayed cancer staging at national institutions.